

July 31, 2025

National Stock Exchange of India Limited
Exchange Plaza,
Plot No. C/1, G Block,
Bandra Kurla Complex, Bandra (E)
Mumbai – 400 051

BSE Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400 001

Symbol: LALPATHLAB

Scrip Code: 539524

Sub: Outcome of Board Meeting held on July 31, 2025

Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“the Listing Regulations”)

Dear Sir/ Madam,

Please take note that the Board of Directors in their meeting held today i.e. July 31, 2025, inter-alia considered and approved the following(s):

Financial Results

1. Un-audited (Standalone & Consolidated) Financial Results of the Company for the Quarter ended June 30, 2025.

A signed copy of the above Financial Results (Standalone & Consolidated) along with Limited Review Report issued by the Statutory Auditors thereon under Regulation 33 of the Listing Regulations is attached herewith as **Annexure- A**.

Interim Dividend

2. Declaration of Interim Dividend of INR 6/- per equity share (@ 60% on a face value of INR 10/- each) for the financial year 2025-26. The record date for the purpose of payment of Interim Dividend shall be August 06, 2025.

The Interim Dividend will be dispatched/ credited within 30 days of its declaration.

Policy

3. Amendment in Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information (“Code”). The Amended Code is attached herewith as **Annexure- B**.

The Board Meeting commenced at 11:00 A.M. (IST) and concluded at 01:15 P.M (IST).

We request you to please take the same on record.

Thanking You,
Yours Faithfully,

For **Dr. Lal PathLabs Limited**

Vinay Gujral
Company Secretary & Compliance Officer
Encl.: As above


INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF
Dr. LAL PATHLABS LIMITED

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of Dr. Lal PathLabs Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter ended June 30, 2025 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities:
 - a) Dr. Lal PathLabs Limited, the Parent company
 - b) Paliwal Diagnostics Private Limited, a subsidiary company
 - c) Dr. Lal PathLabs Nepal Private Limited, a subsidiary company
 - d) Dr. Lal PathLabs Bangladesh Private Limited, a subsidiary company
 - e) Dr. Lal Ventures Private Limited, a subsidiary company
 - f) PathLabs Unifiers Private Limited, a subsidiary company
 - g) Dr. Lal PathLabs Kenya Private Limited, a subsidiary company (dissolved vide date of publication of gazette notification w.e.f. 13 September, 2024)
 - h) Suburban Diagnostics (India) Private Limited, a subsidiary company (voluntary liquidated on 11 February, 2025 with distribution of business undertaking to the Parent Company on a going concern basis)
 - i) Centrapath Labs Private Limited, a step-down subsidiary company
 - j) APRL PathLabs Private Limited, a step-down subsidiary company
 - k) Chanre Laboratory Private Limited, a step-down subsidiary company



**Deloitte
Haskins & Sells LLP**

5. Based on our review conducted and procedures performed as stated in paragraph 3 above nothing has come to our attention that causes us to believe that the Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. The Consolidated Unaudited Financial Results include the unaudited financial information of two subsidiary companies which have not been reviewed by their auditors and have been approved and furnished to us by the Management, whose financial results reflect total revenue of Rupees 51.43 Million, total loss after tax of Rupees 0.79 Million and total comprehensive loss of Rupees 0.72 Million for the quarter ended June 30, 2025, as considered in the Statement. Our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on such unaudited financial information certified by the Management. According to the information and explanations given to us by the Management, these financial results are not material to the Group.

Our conclusion on the Statement in respect of matter stated in para 6 above is not modified with respect to our reliance on the financial results certified by the Management.

For **DELOITTE HASKINS & SELLS LLP**
Chartered Accountants
(Firm Registration No.: 117366W/W-100018)

Place: New Delhi
Date: July 31, 2025





RASHIM TANDON
Partner
Membership No: 95540
(UDIN: 25095540BMOXIN6975)

Statement of Consolidated Unaudited Financial Results for the quarter ended 30 June, 2025

(Rs. in million except as stated)

Particulars	3 months ended 30 June, 2025	Preceding 3 months ended 31 March, 2025	Corresponding 3 months ended in previous year 30 June, 2024	Previous year ended 31 March, 2025
	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
		(See note iv)	(See note vii & viii)	
1 Income				
(a) Revenue from operations	6,698	6,026	6,019	24,614
(b) Other income	281	258	206	934
Total Income	6,979	6,284	6,225	25,548
2 Expenses				
(a) Cost of materials consumed	1,289	1,178	1,194	4,815
(b) Employee benefits expense	1,323	1,154	1,166	4,824
(c) Finance costs	47	50	60	223
(d) Depreciation and amortisation expense	346	364	347	1,419
(e) Fees to collection centers/channel partners	922	776	837	3,417
(f) Other expenses	1,241	1,228	1,122	4,603
Total expenses	5,168	4,750	4,726	19,301
3 Profit before tax	1,811	1,534	1,499	6,247
4 Tax expense				
(a) Current tax	450	393	448	1,720
(b) Deferred tax	21	(414)	(27)	(395)
Total tax expense	471	(21)	421	1,325
5 Profit for the period (A)	1,340	1,555	1,078	4,922
6 Other comprehensive income/(loss)				
Items that will not be reclassified to profit or loss				
-Remeasurement of the defined benefit obligations	(12)	(36)	(2)	(49)
-Income tax in relation to the items that will not be reclassified to profit or loss	3	11	-	13
Items that may be reclassified to profit or loss				
-Exchange differences on translation of foreign operations	-	(1)	1	-
Total other comprehensive income/ (loss) (B)	(9)	(26)	(1)	(36)
7 Total comprehensive income (A+B)	1,331	1,529	1,077	4,886
Profit for the period attributable to:				
Owners of the Company	1,324	1,548	1,064	4,871
Non-controlling interest	16	7	14	51
	1,340	1,555	1,078	4,922
Other comprehensive income/(loss) for the period attributable to:				
Owners of the Company	(9)	(26)	(1)	(36)
Non-controlling interest	-	-	-	-
	(9)	(26)	(1)	(36)
Total comprehensive income for the period attributable to:				
Owners of the Company	1,315	1,522	1,063	4,835
Non-controlling interest	16	7	14	51
	1,331	1,529	1,077	4,886
8 Paid-up equity share capital (Face value of Rs. 10 per share)	838	836	835	836
9 Other equity				20,891
10 Earnings per share (Rs.) (Face value of Rs. 10 per share) (not annualised for quarters)				
-Basic	15.88	18.57	12.79	58.48
-Diluted	15.85	18.54	12.76	58.40



Dr. Lal PathLabs Limited

Notes:

- i. The above consolidated results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on 31 July, 2025. The limited review, as required under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, has been completed by the Statutory Auditors for the quarter ended 30 June, 2025 and they have expressed an unmodified conclusion on the aforesaid results.
- ii. The above consolidated results represent consolidated results of the Company and its subsidiaries (together referred to as 'the Group').
- iii. These financial results of the Group have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.
- iv. Figures for the quarter ended 31 March, 2025 are the balancing figures between the audited figures in respect of full financial year and the published year to date unaudited figures up to the third quarter ended 31 December, 2024, which were subjected to limited review.
- v. During the quarter ended 30 June 2025, the Parent Company has issued 183,775 equity shares of face value of Rs. 10 each, to "Dr. Lal Pathlabs Employee Welfare Trust" under Employee Stock Option Plan, 2022 ("ESOP Plan, 2022").
- vi. The Board of Directors of the Parent Company have approved an interim dividend of INR 6 per equity share (face value of INR 10 each) at their meeting held on 31 July, 2025

The Board of Directors of the Parent Company had proposed final dividend of INR 6 per equity share (face value of INR 10 each) for the financial year ended 31 March, 2025. The same was approved by the shareholders in the Annual General Meeting held on 28 June, 2025 and this was paid on 2 July, 2025.

- vii. The Hon'ble Allahabad Bench of the National Company Law Tribunal ('Hon'ble Tribunal' or 'NCLT') sanctioned the Scheme of Amalgamation ('Scheme') between the subsidiaries Paliwal Medicare Private Limited (PMPL) (Transferor Company) and Paliwal Diagnostics Private Limited (PDPL) (Transferee Company) on 3 September, 2024. The appointed date as per Scheme was 1 April, 2021. The Scheme had envisaged transfer of all properties, rights, assets, interests and claims of the Transferor Company to the Transferee Company. Pursuant to the Scheme becoming effective, the amalgamation had been accounted for under the 'pooling of interests' method in accordance with Ind AS 103 "Business Combinations" and the assets, liabilities and reserves of the Transferor Company had been accounted for at their book value, in the books of Transferee Company.
- viii. The Board of the Parent Company had earlier noted approval by the board of Suburban Diagnostics India Private Limited ("SDIPL"), a wholly owned subsidiary of the Company for voluntary liquidation of SDIPL under the provisions of Insolvency and Bankruptcy Code, 2016, wherein the business undertaking of SDIPL was sought to be distributed to the Company on a going concern basis. The shareholders of SDIPL at their Extra-Ordinary General Meeting held on 6 February, 2025 also accorded approval for the voluntary liquidation of SDIPL. On 18 March, 2025, the liquidator of SDIPL based on the approved scheme has distributed the entire business undertaking of SDIPL to the Company, on a going concern basis.

The above distribution resulted in inter-alia recognition of long term service agreements in block of intangible assets in tax books of the Company at fair value on 18 March, 2025. Accordingly, deferred tax credit of INR 408 million has been recognised in statement of profit or loss for the quarter and year ended 31 March 2025.

- ix. During the year ended 31 March 2025, Dr. Lal PathLabs Kenya Private Limited (Wholly Owned Subsidiary), a Company incorporated in the Republic of Kenya, was dissolved and its name was struck off, with effect from the date of publication of gazette notification dated 13 September, 2024.

- x. As at 30 June, 2025, the Parent company has the following subsidiaries:

Subsidiaries

Paliwal Diagnostics Private Limited
Dr. Lal PathLabs Nepal Private Limited
Dr. Lal PathLabs Bangladesh Private Limited
Dr. Lal Ventures Private Limited
PathLabs Unifiers Private Limited


Step-down subsidiaries

Centrapath Labs Private Limited
APRL PathLabs Private Limited
Chanre Laboratory Private Limited

JV/Associate Company- Nil


- xi. The Board of Directors, which has been identified as being the chief operating decision maker (CODM), evaluates the Group's performance, allocates resources based on the analysis of the various performance indicators of the Group as a single unit. Therefore there is no reportable segment for the Group, in accordance with the requirements of Indian Accounting Standard 108- 'Operating Segments', notified under the Companies (Indian Accounting Standard) Rules, 2015.

For and on behalf of the Board of Directors of
Dr. Lal PathLabs Limited



(Hony) Brig. Dr. Arvind Lal
Executive Chairman

Place: New Delhi
Date: 31 July, 2025



INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS


TO THE BOARD OF DIRECTORS OF
Dr. LAL PATHLABS LIMITED

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of Dr. Lal PathLabs Limited ("the Company"), for the quarter ended June 30, 2025 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **DELOITTE HASKINS & SELLS LLP**
Chartered Accountants
(Firm Registration No.: 117366W/W-100018)

Place: New Delhi
Date: July 31, 2025





RASHIM TANDON
Partner
Membership No: 95540
(UDIN: 25095540BMOXIM4002)

Statement of Standalone Unaudited Financial Results for the quarter ended 30 June, 2025

(Rs. in million except as stated)

Particulars	3 months ended 30 June, 2025	Preceding 3 months ended 31 March, 2025	Corresponding 3 months ended in previous year 30 June, 2024	Previous year ended 31 March, 2025
		(See note iii)	(See note vi)	
	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1 Income				
(a) Revenue from operations	6,407	5,772	5,744	23,516
(b) Other income	263	252	309	1,115
Total Income	6,670	6,024	6,053	24,631
2 Expenses				
(a) Cost of materials consumed	1,226	1,113	1,131	4,552
(b) Employee benefits expense	1,258	1,094	1,108	4,584
(c) Finance costs	45	48	58	215
(d) Depreciation and amortisation expense	328	346	327	1,342
(e) Fees to collection centers/channel partners	903	758	823	3,351
(f) Other expenses	1,186	1,216	1,069	4,374
Total expenses	4,946	4,575	4,516	18,418
3 Profit before tax	1,724	1,449	1,537	6,213
4 Tax expense				
(a) Current tax	409	380	418	1,633
(b) Deferred tax	22	(415)	(26)	(393)
Total tax expense	431	(35)	392	1,240
5 Profit for the period (A)	1,293	1,484	1,145	4,973
6 Other comprehensive income/(loss)				
Items that will not be reclassified to profit or loss	(12)	(35)	(2)	(48)
-Remeasurement of the defined benefit obligations				
-Income tax in relation to the items that will not be reclassified to profit or loss	3	10	-	12
Total other comprehensive income/(loss) (B)	(9)	(25)	(2)	(36)
7 Total comprehensive income (A+B)	1,284	1,459	1,143	4,937
8 Paid-up equity share capital (Face value of Rs. 10 per share)	838	836	835	836
9 Other equity				20,506
10 Earnings per share (Rs.) (Face value of Rs. 10 per share) (not annualised for quarters)				
- Basic	15.51	17.80	13.76	59.70
- Diluted	15.49	17.78	13.73	59.61



Dr. Lal PathLabs Limited

Notes:

- i. The above results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on 31 July, 2025. The limited review, as required under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, has been completed by the Statutory Auditors for the quarter ended 30 June, 2025 and they have expressed an unmodified conclusion on the aforesaid results.
- ii. These financial results have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.
- iii. Figures for the quarter ended 31 March, 2025 are the balancing figures between the audited figures in respect of full financial year and the published year to date unaudited figures up to the third quarter ended 31 December, 2024, which were subjected to limited review.
- iv. During the quarter ended 30 June, 2025, the Company has issued 183,775 equity shares of face value of Rs. 10 each, to "Dr. Lal Pathlabs Employee Welfare Trust" under Employee Stock Option Plan, 2022 ("ESOP Plan, 2022").
- v. The Board of Directors of the Company have approved an interim dividend of Rs. 6 per equity share (face value of INR 10 each) at their meeting held on 31 July, 2025

The Board of Directors of the Company had proposed final dividend of INR 6 per equity share (face value of INR 10 each) for the financial year ended 31 March, 2025. The same was approved by the shareholders in the Annual General Meeting held on 28 June, 2025 and this was paid on 2 July, 2025

- vi. The Board of the Company had earlier noted approval by the board of Suburban Diagnostics India Private Limited ("SDIPL"), a wholly owned subsidiary of the Company for voluntary liquidation of SDIPL under the provisions of Insolvency and Bankruptcy Code, 2016, wherein the business undertaking of SDIPL was sought to be distributed to the Company on a going concern basis. The shareholders of SDIPL at their Extra-Ordinary General Meeting held on 6 February, 2025 also accorded approval for the voluntary liquidation of SDIPL. On 18 March, 2025, the liquidator of SDIPL based on the approved scheme has distributed the entire business undertaking of SDIPL to the Company, on a going concern basis.


The said distribution of business undertaking has been accounted for using the pooling of interests method in accordance with Appendix C of Ind AS 103 'Business combinations of entities under common control'. Accordingly, the comparative financial information for the previous periods have been restated to give effect of the consummation of business undertaking from beginning of the period disclosed and all assets, liabilities and reserves of SDIPL together with intangible assets - long term service agreements and related deferred tax liability has been recognised in the Standalone Financial Statement.

The above distribution resulted in inter-alia recognition of long term service agreements in block of intangible assets in tax books of the Company at fair value on 18 March, 2025. Accordingly, deferred tax credit of INR 408 million has been recognised in statement of profit or loss for the quarter and year end 31 March, 2025.

Accordingly, the results for the quarter ended 30 June, 2024, quarter have been restated to give effect of the liquidation.

- vii. During the year ended 31 March 2025, Dr. Lal PathLabs Kenya Private Limited (Wholly Owned Subsidiary), a Company incorporated in the Republic of Kenya, was dissolved and its name was struck off, with effect from the date of publication of gazette notification dated 13 September, 2024.
- viii. The Board of Directors of the Company, which has been identified as being the chief operating decision maker (CODM), evaluates the Company's performance, allocates resources based on the analysis of the various performance indicators of the Company as a single unit. Therefore there is no reportable segment for the Company, in accordance with the requirements of Indian Accounting Standard 108- 'Operating Segments', notified under the Companies (Indian Accounting Standard) Rules, 2015.

For and on behalf of the Board of Directors of
Dr. Lal PathLabs Limited



(Hony) Brig. Dr. Arvind Lal
Executive Chairman

Place: New Delhi
Date: 31 July, 2025



Dr. Lal PathLabs Limited

Corporate Identity Number: L74899DL1995PLC065388

Regd. Office: Block E, Sector - 18, Rohini, New Delhi – 110085

Corporate Office: 12th Floor, Tower B, SAS Tower, Medicity, Gurugram - 122001

Website: www.lalpathlabs.com | **Phone:** +91 124 3016500 | **Fax:** +91 124 4234468

CODE OF PRACTICES AND PROCEDURES FOR FAIR DISCLOSURES OF UNPUBLISHED PRICE SENSITIVE INFORMATION

[under Regulation 8(1) of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015]

1. Introduction

In terms of Regulation 8(1) of the SEBI (Prohibition of Insider Trading) Regulations, 2015 (“Regulations”), Dr. Lal PathLabs Limited required to formulate a Code of Practices and Procedures for Fair Disclosures of Unpublished Price Sensitive Information (“Code”).

2. Objective of the Code

The Company endeavors to preserve the confidentiality of Unpublished Price Sensitive Information (“UPSI”) and to prevent its misuse. To achieve this objective and in compliance with the aforesaid regulations, the Board of Directors have adopted this code.

The Code ensures timely and adequate disclosure of UPSI which could impact the prices of its securities and maintains the uniformity, transparency and fairness in dealing with all its stakeholders.

3. Definitions

- a. **“Chief Investors Relations Officer” (“CIRO”)** means the Company Secretary & Compliance Officer of the Company.
- b. **“Company”** means Dr. Lal PathLabs Limited (hereinafter referred as “the Company”)
- c. **“Compliance Officer”** for the purpose of these regulations means the Company Secretary of the Company.
- d. **“Mainstream Media”** shall include print or electronic mode (as amended by SEBI from time to time) of the following:
 - i. Newspapers registered with the Registrar of Newspapers for India;
 - ii. News Channels permitted by Ministry of Information and Broadcasting under Government of India;
 - iii. Content published by the publisher of news and current affairs content as defined under the Information Technology (Intermediary Guidelines and Digital Media Ethics Code) Rules, 2021; and
 - iv. Newspapers or news channels or news and current affairs content similarly registered or permitted or regulated, as the case may be, in jurisdictions outside India.

Dr. Lal PathLabs Limited

- e. **“Unpublished Price Sensitive Information”** (“UPSI”) means any information, relating to a Company or its securities, directly or indirectly, that is not generally available which upon becoming generally available, is likely to materially affect the price of the Securities and shall ordinarily including but not restricted to, information relating to the following:
- (i) Financial Results;
 - (ii) Dividends;
 - (iii) Change in Capital Structure;
 - (iv) Mergers, De-mergers, Acquisitions, Delisting, Disposals and Expansion of Business, award or termination of order/contracts not in the normal course of and such other transactions;
 - (v) Changes in Key Managerial Personnel, other than due to superannuation or end of term, and resignation of a Statutory Auditor or Secretarial Auditor;
 - (vi) Change in rating(s), other than ESG rating(s);
 - (vii) Fund raising proposed to be undertaken;
 - (viii) Agreements, by whatever name called, which may impact the management or control of the Company;
 - (ix) Fraud or defaults by the Company, its promoter, director, key managerial personnel, or subsidiary or arrest of key managerial personnel, promoter or director of the Company, whether occurred within India or abroad;
 - (x) Resolution plan/ restructuring or one-time settlement in relation to loans/borrowings from banks/financial institutions;
 - (xi) Admission of winding-up petition filed by any party /creditors and admission of application by the Tribunal filed by the corporate applicant or financial creditors for initiation of corporate insolvency resolution process against the Company as a corporate debtor, approval of resolution plan or rejection thereof under the Insolvency and Bankruptcy Code, 2016;
 - (xii) Initiation of forensic audit, by whatever name called, by the Company or any other entity for detecting mis-statement in financials, misappropriation/ siphoning or diversion of funds and receipt of final forensic audit report;
 - (xiii) Action(s) initiated or orders passed within India or abroad, by any regulatory, statutory, enforcement authority or judicial body against the Company or its directors, key managerial personnel, promoter or subsidiary, in relation to the Company;
 - (xiv) Outcome of any litigation(s) or dispute(s) which may have an impact on the Company;
 - (xv) Giving of guarantees or indemnity or becoming a surety, by whatever named called, for any third party, by the Company not in the normal course of business;
 - (xvi) Granting, withdrawal, surrender, cancellation or suspension of key licenses or regulatory approvals and other material event(s) as may be specified under Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, as amended from time to time.

The word and expression used and not defined in this code but defined in SEBI (Prohibition of Insider Trading) Regulations, 2015, SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, Securities Contracts (Regulation) Act, 1956, The Depositories Act, 1996 and Companies Act, 2013 shall have the meaning assigned to them in those legislations.

The Company will adhere to the following guidelines so as to ensure fair disclosure of events and occurrence(s) that may impact price of its securities:

Dr. Lal PathLabs Limited

4. Norms for disclosure of UPSI

a. Prompt public disclosure of UPSI

UPSI shall be disclosed by the Company to the Stock Exchange(s) promptly when credible & concrete information is available for making the same generally available and shall also be uploaded on the Company's official website (www.lalpathlabs.com), in compliance of regulatory requirements.

b. Uniform and Universal dissemination of UPSI

The disclosure of UPSI shall be on a continuous, immediate, uniform, universally disseminated and due care will be taken to avoid selective disclosure.

c. Overseeing and coordinating disclosure(s)

The CIRO shall oversee corporate disclosures and deal with dissemination of information and disclosure of UPSI.

The CIRO shall be responsible for ensuring that the Company complies with continuous disclosure requirements and for overseeing and coordinating disclosure of UPSI to Stock Exchanges, on the website of the Company and to the media, if required.

If any information is accidentally disclosed without prior approval of CIRO the person responsible may inform the CIRO immediately. In such event of inadvertent disclosure of UPSI, the CIRO shall take prompt action to ensure such information is generally available.

In addition to the CIRO, the following persons are also authorized to communicate with the Investors/ media:

- i. Chairman
- ii. Managing Director
- iii. Executive Director(s)
- iv. CEO &
- v. CFO

d. Responding to market rumours

The CIRO shall respond to any queries on news reports and requests for verification of market rumours by regulatory authorities including Stock Exchanges on behalf of the Company.

The CIRO in consultation with Managing Director/ Chief Executive Officer and Chief Financial Officer shall provide proper and equitable response i.e. Confirm/ Deny/ Clarify on reported event or information in the mainstream media, as required under the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 and SEBI (Prohibition of Insider Trading) Regulations, 2015.

Dr. Lal PathLabs Limited

5. Process of disseminating information in order to make the UPSI generally available

- Disclosure/dissemination of information may be done through various media so as to achieve maximum reach and quick dissemination.
- The website of the Company may provide a means of giving investors a direct access to analyst briefing material, significant background information and questions & answers.

6. Manner of dealing with analyst and research personnel

- Only Public information to be provided** – A Company shall provide only public information to the analyst/research persons/large investors like institutions.
- Recording of discussion** - In order to avoid misquoting or misrepresentation, it is desirable that at least two Company's representatives be present at meetings with analysts, brokers or institutional investors. The Company shall adopt best practices to make transcripts or records of proceedings of such meetings available on the website of the Company to ensure official confirmation and documentation of disclosures made.
- Handling of unanticipated questions** –The Company should be careful when dealing with analysts' questions that raise issues outside the intended scope of discussion. Unanticipated questions may be taken on notice and a considered response given later. If the answer includes UPSI, a public disclosure, if considered appropriate, should be made before responding.

7. UPSI on Need-to-Know basis

UPSI shall be handled on a “need to know” basis i.e. it shall be disclosed only to those where such communication is in furtherance of legitimate purposes, performance of duties or discharge of legal obligations.

8. Policy for Determination of Legitimate Purposes

“Legitimate Purpose” shall include sharing of unpublished price sensitive information in the ordinary course of business by an insider with partners, collaborators, lenders, customers, suppliers, merchant bankers, legal advisors, auditors, insolvency professionals or other advisors or consultants, provided that such sharing has not been carried out to evade or circumvent the prohibitions of these regulations.

Any person in receipt of unpublished price sensitive information pursuant to a “Legitimate Purpose” shall be considered an “insider” for purposes of these regulations and due notice shall be given to such persons to maintain confidentiality of such unpublished price sensitive information in compliance with these regulations.

A structured digital database shall be maintained containing the nature of unpublished price sensitive information and the names of such persons who have shared the information and also the names of such persons or entities as the case may be with whom information is shared for legitimate purpose along with the Permanent Account Number or any other identifier authorized by law where Permanent Account Number is not available. Such database shall

Dr. Lal PathLabs Limited

not be outsourced and shall be maintained internally with adequate internal controls and checks such as time stamping and audit trails to ensure non-tampering of the database.

The Company shall ensure that the structured digital database is preserved for a period of not less than eight years after completion of the relevant transactions and in the event of receipt of any information from SEBI regarding any investigation or enforcement proceedings, the relevant information in the structured digital database shall be preserved till the completion of such proceedings.

Following factors must be satisfied while determining what constitutes a legitimate purpose:

- i. Must be shared in the ordinary of course of business or for Corporate Purpose;
- ii. Required to be done in furtherance of fiduciary duties or in fulfillment of any statutory or contractual obligation;
- iii. The action is executed in a manner which is considered as fair and transparent; and
- iv. Information shared is in the interest of Company and should not result into a personal benefit to the Insider

9. Disclosure of Code on Public Domain

This Code and any amendment thereof shall be published on the Company's website www.lalpathlabs.com.

10. Amendments to the Code

The Board of Directors may review or amend this code, in whole or in part, from time to time, as per the requirements of the Companies Act, 2013 or SEBI (Prohibition of Insider Trading) Regulations, 2015 or any other enactments/rules/amendments as may be made applicable.

This Code is in addition to and not in derogation of the provisions of the SEBI (Prohibition of Insider Trading) Regulations, 2015. In case of any inconsistency, the provisions of the Regulations shall prevail.